ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Japan’s Mitsubishi Tanabe Pharma has agreed to acquire the majority of vaccines developer Medicago in a deal that values the company at about $357 million. Tobacco giant Philip Morris will continue to own 40% of the company. Medicago, which is based in Quebec City, is developing vaccines that can be grown in plants, including tobacco. Earlier this year, Medicago signed an agreement with Mitsubishi Tanabe’s parent company to evaluate Mitsubishi’s closed system for growing a plant related to tobacco as a pharmaceutical protein source.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X